|
DE102004024454A1
(de)
*
|
2004-05-14 |
2005-12-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
|
|
GB0426164D0
(en)
|
2004-11-29 |
2004-12-29 |
Novartis Ag |
Organic compounds
|
|
RU2442771C2
(ru)
|
2005-08-08 |
2012-02-20 |
Арджента Дискавери Лтд |
Производные бицикло[2,2,1]гепт-7-иламина и их применения
|
|
GB0516313D0
(en)
|
2005-08-08 |
2005-09-14 |
Argenta Discovery Ltd |
Azole derivatives and their uses
|
|
TW200738658A
(en)
|
2005-08-09 |
2007-10-16 |
Astrazeneca Ab |
Novel compounds
|
|
TW200745067A
(en)
|
2006-03-14 |
2007-12-16 |
Astrazeneca Ab |
Novel compounds
|
|
TW200833670A
(en)
|
2006-12-20 |
2008-08-16 |
Astrazeneca Ab |
Novel compounds 569
|
|
BRPI0807806A2
(pt)
*
|
2007-01-25 |
2014-06-17 |
Boehringer Ingelheim Int |
" processo para a fabricação de beta-miméticos ".
|
|
GB0702458D0
(en)
|
2007-02-08 |
2007-03-21 |
Astrazeneca Ab |
Salts 668
|
|
CA2679059A1
(en)
|
2007-02-28 |
2008-09-04 |
Cipla Limited |
Process for preparing isomers of carmoterol
|
|
JP2011524896A
(ja)
|
2008-06-18 |
2011-09-08 |
アストラゼネカ・アクチエボラーグ |
呼吸器障害の処置用のベータ2−アドレナリン受容体アゴニストとして作用するベンズオキサジノン誘導体
|
|
US8236786B2
(en)
|
2008-08-07 |
2012-08-07 |
Pulmagen Therapeutics (Inflammation) Limited |
Respiratory disease treatment
|
|
PL2379507T3
(pl)
|
2008-12-30 |
2014-03-31 |
Pulmagen Therapeutics Inflammation Ltd |
Związki sulfonamidu do leczenia zaburzeń układu oddechowego
|
|
WO2010150014A1
(en)
|
2009-06-24 |
2010-12-29 |
Pulmagen Therapeutics (Inflammation) Limited |
5r- 5 -deuterated glitazones for respiratory disease treatment
|
|
GB0918924D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Azaindole derivatives
|
|
GB0918923D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Aminothiazole derivatives
|
|
GB0918922D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Aminopyridine derivatives
|
|
WO2011098746A1
(en)
|
2010-02-09 |
2011-08-18 |
Pulmagen Therapeutics (Inflammation) Limited |
Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
|
|
GB201002224D0
(en)
|
2010-02-10 |
2010-03-31 |
Argenta Therapeutics Ltd |
Respiratory disease treatment
|
|
GB201002243D0
(en)
|
2010-02-10 |
2010-03-31 |
Argenta Therapeutics Ltd |
Respiratory disease treatment
|
|
JO3192B1
(ar)
|
2011-09-06 |
2018-03-08 |
Novartis Ag |
مركب بنزوثيازولون
|
|
SI2890687T1
(sl)
|
2012-08-30 |
2017-10-30 |
Novartis Ag |
Soli benzotiazolonske spojine kot agonist beta-2-adrenoceptorja
|
|
US9784726B2
(en)
|
2013-01-08 |
2017-10-10 |
Atrogi Ab |
Screening method, a kit, a method of treatment and a compound for use in a method of treatment
|
|
WO2014132205A1
(en)
|
2013-02-28 |
2014-09-04 |
Novartis Ag |
Formulation comprising benzothiazolone compound
|
|
GB201714736D0
(en)
|
2017-09-13 |
2017-10-25 |
Atrogi Ab |
New compounds and uses
|
|
GB201714740D0
(en)
|
2017-09-13 |
2017-10-25 |
Atrogi Ab |
New compounds and uses
|
|
GB201714734D0
(en)
|
2017-09-13 |
2017-10-25 |
Atrogi Ab |
New compounds and uses
|
|
GB201714745D0
(en)
|
2017-09-13 |
2017-10-25 |
Atrogi Ab |
New compounds and uses
|
|
GB201903832D0
(en)
|
2019-03-20 |
2019-05-01 |
Atrogi Ab |
New compounds and methods
|
|
GB202205895D0
(en)
|
2022-04-22 |
2022-06-08 |
Atrogi Ab |
New medical uses
|
|
CN120583945A
(zh)
|
2023-01-20 |
2025-09-02 |
阿托基公司 |
用于治疗或预防肌肉消耗的β2-肾上腺素能受体激动剂
|
|
GB202302225D0
(en)
|
2023-02-16 |
2023-04-05 |
Atrogi Ab |
New medical uses
|
|
GB202303229D0
(en)
|
2023-03-06 |
2023-04-19 |
Atrogi Ab |
New medical uses
|
|
GB202403169D0
(en)
|
2024-03-05 |
2024-04-17 |
Atrogi Ab |
New medical uses
|
|
WO2025238248A1
(en)
|
2024-05-17 |
2025-11-20 |
Atrogi Ab |
USE OF β2-ADRENERGIC RECEPTOR AGONISTS IN TREATING MUSCLE WASTING
|